Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Toward a comprehensive long term nicotine policy.

Gray N, Henningfield JE, Benowitz NL, Connolly GN, Dresler C, Fagerstrom K, Jarvis MJ, Boyle P.

Tob Control. 2005 Jun;14(3):161-5. Review.

2.

Nicotine psychopharmacology: policy and regulatory.

Henningfield JE, Zeller M.

Handb Exp Pharmacol. 2009;(192):511-34. doi: 10.1007/978-3-540-69248-5_18. Review.

PMID:
19184661
3.
4.

Tobacco, nicotine and harm reduction.

Le Houezec J, McNeill A, Britton J.

Drug Alcohol Rev. 2011 Mar;30(2):119-23. doi: 10.1111/j.1465-3362.2010.00264.x. Review.

PMID:
21375611
5.

Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association.

Henningfield JE, Benowitz NL, Slade J, Houston TP, Davis RM, Deitchman SD.

Tob Control. 1998 Autumn;7(3):281-93. Review.

6.

Policy options to reduce tobacco-caused mortality.

Sweanor DT.

J Addict Dis. 1999;18(3):1-11. Review.

PMID:
10507577
7.

Smokeless tobacco use: harm reduction or induction approach?

Hatsukami DK, Lemmonds C, Tomar SL.

Prev Med. 2004 Mar;38(3):309-17. Review.

PMID:
14766113
8.

[Use of nicotine containing products in weaning from tobacco].

Zellweger JP.

Rev Med Suisse Romande. 1998 Jun;118(6):521-5. Review. French. No abstract available.

PMID:
9689861
9.

Snuffing out cigarette sales and the smoking deaths epidemic.

Laugesen M.

N Z Med J. 2007 Jun 15;120(1256):U2587. Review.

PMID:
17589555
10.

Nicotine and non-nicotine smoking cessation pharmacotherapies.

Frishman WH, Mitta W, Kupersmith A, Ky T.

Cardiol Rev. 2006 Mar-Apr;14(2):57-73. Review.

PMID:
16493243
11.

Smokeless tobacco: the epidemiology and politics of harm.

Phillips CV, Heavner KK.

Biomarkers. 2009 Jul;14 Suppl 1:79-84. doi: 10.1080/13547500902965476. Review.

PMID:
19604065
12.

Are nicotine replacement strategies to facilitate smoking cessation safe?

Lavelle C, Birek C, Scott DA.

J Can Dent Assoc. 2003 Oct;69(9):592-7. Review.

13.

Pharmacotherapy for tobacco dependence.

Fant RV, Buchhalter AR, Buchman AC, Henningfield JE.

Handb Exp Pharmacol. 2009;(192):487-510. doi: 10.1007/978-3-540-69248-5_17. Review.

PMID:
19184660
14.

The emerging phenomenon of electronic cigarettes.

Caponnetto P, Campagna D, Papale G, Russo C, Polosa R.

Expert Rev Respir Med. 2012 Feb;6(1):63-74. doi: 10.1586/ers.11.92. Review.

PMID:
22283580
15.

Smoking cessation pharmacotherapy.

Frishman WH.

Ther Adv Cardiovasc Dis. 2009 Aug;3(4):287-308. doi: 10.1177/1753944709335754. Epub 2009 Jun 2. Review.

PMID:
19491139
16.

The most addictive drug, the most deadly substance: smoking cessation tactics for the busy clinician.

Crane R.

Prim Care. 2007 Mar;34(1):117-35. Review. No abstract available.

PMID:
17481990
17.

The use of iontophoresis in the administration of nicotine and new non-nicotine drugs through the skin for smoking cessation.

Escobar-Chávez JJ, Merino V, López-Cervantes M, Rodríguez-Cruz IM, Quintanar-Guerrero D, Ganem-Quintanar A.

Curr Drug Discov Technol. 2009 Sep;6(3):171-85. Epub 2009 Sep 1. Review.

PMID:
19496753
18.

Regulatory imbalance between medicinal and non-medicinal nicotine.

Sweanor D.

Addiction. 2000 Jan;95 Suppl 1:S25-8. Review.

PMID:
10723819
19.

[European experiences concerning schedules of the fight against the tobacco addiction].

Kurpas D, Steciwko A.

Przegl Lek. 2006;63(10):1123-5. Review. Polish.

PMID:
17288234
20.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839

Supplemental Content

Support Center